tag:blogger.com,1999:blog-36634196.post2358832330885079750..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: Sticker Shock May Open Innovation in PharmaChris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-36634196.post-68820539954666219552010-03-24T13:36:54.000-05:002010-03-24T13:36:54.000-05:00I'm working on a conference in this arena - an...I'm working on a conference in this arena - and would love to speak with you - I can be reached on 561 674 0083.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36634196.post-26025654577962335482009-03-18T13:20:00.000-05:002009-03-18T13:20:00.000-05:00This was originally suggested few years back by th...This was originally suggested few years back by then Chairman of Intel Corp. Andy Grove in his JAMA article....it is worth reading. I had a chance to work with him on Intel Bioscience's early efforts...and it looks like finally market conditions are driving pharma companies to Andy's vision for pharma R&D.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36634196.post-60791636770519240742009-03-04T17:15:00.000-05:002009-03-04T17:15:00.000-05:00A very interesting development. A good starting po...A very interesting development. A good starting point could be in sharing best practices, particularly in areas such as adoption of novel technologies and streamlining the development process.<BR/><BR/>At Xceleron we are introducing many novel ways of gaining more information in early clinical trials through the use of Microdosing and Microtracers, to provide better insight into human phamacokinetics, metabolite profiles, and intravenous pharmacokinetics. Although we have many supporters of the technology, each new company we work with goes through the same process of evaluation before adoption.Ian Halletthttps://www.blogger.com/profile/05331014022337353377noreply@blogger.com